Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein Zuid 32, 6525 GA, Nijmegen, The Netherlands.
Department of Anesthesiology, Pain and Palliative Medicine, Radboud University Medical Center, Geert Grooteplein 10, 6525 GA, Nijmegen, The Netherlands.
Cancer Immunol Immunother. 2018 Nov;67(11):1789-1796. doi: 10.1007/s00262-018-2205-1. Epub 2018 Jul 11.
Dendritic cells (DCs) are widely used in DC-based immunotherapies because of their capacity to steer immune responses. So far treatment success is limited and more functional knowledge on how DCs initiate and stably drive specific responses is needed. Many intrinsic and extrinsic factors contribute to how DCs skew the immune response towards immunity or tolerance. The origin and type of DC, its maturation status, but also factors they encounter in the in vitro or in vivo microenvironment they reside in during differentiation and maturation affect this balance. Treatment success of DC vaccines will, therefore, also depend on the presence of these factors during the process of vaccination. Identification and further knowledge of natural and pharmacological compounds that modulate DC differentiation and function towards a specific response may help to improve current DC-based immunotherapies. This review focuses on factors that could improve the efficacy of DC vaccines in (pre-)clinical studies to enhance DC-based immunotherapy, with a particular emphasis on compounds acting on prostanoid or nuclear receptor families.
树突状细胞 (DC) 因其能够引导免疫反应而被广泛应用于基于 DC 的免疫疗法。但到目前为止,治疗效果有限,因此需要更多关于 DC 如何启动和稳定驱动特定反应的功能知识。许多内在和外在因素影响 DC 如何使免疫反应偏向免疫或耐受。DC 的起源和类型、其成熟状态,以及它们在分化和成熟过程中在体外或体内微环境中遇到的因素,都会影响这种平衡。因此,DC 疫苗的治疗效果也将取决于接种过程中这些因素的存在。鉴定和进一步了解可调节 DC 分化和功能以产生特定反应的天然和药理学化合物,可能有助于改进现有的基于 DC 的免疫疗法。本综述重点介绍了可提高 (临床前) 研究中 DC 疫苗疗效以增强基于 DC 的免疫疗法的因素,特别强调了作用于前列腺素或核受体家族的化合物。